Discontinue Diltiazem 90 mg
In a patient with systolic blood pressure of 142 mm Hg requiring an increase to 160 mm Hg, diltiazem should be discontinued first. This is the most appropriate choice among the three medications listed.
Rationale for Discontinuing Diltiazem
Diltiazem is a nondihydropyridine calcium channel blocker that provides significant blood pressure lowering effects. Among your three options, it has the most potent antihypertensive effect and its discontinuation will most reliably allow blood pressure to rise to your target of 160 mm Hg.
Key considerations supporting diltiazem discontinuation:
Nondihydropyridine CCBs should be avoided in patients with heart failure with reduced ejection fraction (HFrEF) due to negative inotropic effects 1, 2, 3. If this patient has any degree of systolic dysfunction, diltiazem is contraindicated regardless of blood pressure considerations.
Diltiazem at 90 mg daily provides substantial blood pressure reduction. Clinical trials demonstrate diltiazem monotherapy reduces systolic BP by approximately 11-15 mm Hg and diastolic BP by 11-13 mm Hg 4, 5.
The medication has no compelling indication for continuation in most clinical scenarios (unlike diuretics for volume management or ARBs for renal protection).
Why Not the Other Medications?
Furosemide (Lasix) 40 mg:
- This is a loop diuretic primarily used for volume management rather than blood pressure control 6
- Loop diuretics are "less effective than thiazide diuretics in lowering BP" 3
- If the patient has any volume overload, heart failure, or significant renal impairment (GFR <30 mL/min), furosemide serves a critical role beyond blood pressure management 1, 2
- Discontinuing furosemide risks volume reaccumulation and clinical decompensation
Losartan/HCTZ 40 mg/12.5 mg:
- This combination provides dual mechanisms of blood pressure reduction but also offers important organ protection
- ARBs are first-line agents for hypertension and provide cardiovascular and renal protection 7, 1, 2
- The LIFE study demonstrated losartan-based therapy reduced stroke risk and cardiovascular mortality compared to beta-blocker therapy 8
- Thiazide diuretics are cornerstone antihypertensive agents with proven cardiovascular outcome benefits 7, 9
- This combination should be preserved unless there are specific contraindications
Clinical Context Requiring Higher Blood Pressure Target
The unusual clinical scenario of raising blood pressure to 160 mm Hg suggests several possible contexts:
- Severe bilateral renal artery stenosis where perfusion pressure is critical
- Critical cerebrovascular stenosis requiring higher perfusion pressure
- Acute stroke where permissive hypertension is indicated
- Severe aortic stenosis with fixed cardiac output
In any of these scenarios, diltiazem remains the safest medication to discontinue as it provides no specific organ protection and may worsen certain conditions (particularly aortic stenosis through negative inotropy).
Implementation Strategy
Discontinue diltiazem 90 mg immediately and monitor blood pressure closely:
- Check blood pressure within 24-48 hours after discontinuation
- Expect systolic BP to rise by 10-15 mm Hg within 3-5 days as the medication clears (diltiazem half-life is 3-4.5 hours for immediate release, longer for sustained release formulations)
- If blood pressure does not reach target of 160 mm Hg after diltiazem discontinuation, then consider reducing the losartan/HCTZ dose by half (to 20 mg/6.25 mg)
- Maintain furosemide unless there is clear evidence of volume depletion
Important Caveats
If the patient has atrial fibrillation with rapid ventricular response, diltiazem serves a critical rate-control function beyond blood pressure management. In this specific scenario, you would need to reduce the losartan/HCTZ instead, as diltiazem's rate-control properties would be essential 1, 2.
Monitor for rebound effects after diltiazem discontinuation, though these are uncommon with calcium channel blockers compared to beta-blockers or clonidine.